Virpax Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Virpax Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • Virpax Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$2.01M, a 66.5% increase year-over-year.
  • Virpax Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$13.2M, a 2.76% increase year-over-year.
  • Virpax Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$15.2M, a 29.8% increase from 2022.
  • Virpax Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$21.7M, a 79.6% decline from 2021.
  • Virpax Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$12.1M, a 178% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$13.2M -$2.01M +$3.99M +66.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$17.2M -$3.45M -$337K -10.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-14
Q1 2024 -$16.9M -$3.22M -$1.7M -112% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-14
Q4 2023 -$15.2M -$4.56M -$1.57M -52.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-26
Q3 2023 -$13.6M -$5.99M +$1.65M +21.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$15.3M -$3.11M +$2.77M +47.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-14
Q1 2023 -$18M -$1.52M +$3.62M +70.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-14
Q4 2022 -$21.7M -$2.99M +$1.13M +27.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-26
Q3 2022 -$22.8M -$7.64M -$4.43M -138% Jul 1, 2022 Sep 30, 2022 10-Q 2023-12-07
Q2 2022 -$18.4M -$5.88M -$3.54M -151% Apr 1, 2022 Jun 30, 2022 10-Q 2023-12-07
Q1 2022 -$14.8M -$5.14M -$2.76M -116% Jan 1, 2022 Mar 31, 2022 10-Q 2023-12-07
Q4 2021 -$12.1M -$4.12M -$3.41M -484% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 -$8.64M -$3.22M -$1.51M -88.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$7.14M -$2.34M -$1.07M -84.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$6.06M -$2.38M -$1.72M -262% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 -$4.34M -$705K Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$1.71M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$1.27M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 -$656K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.